KENNETH R HESS to Male
This is a "connection" page, showing publications KENNETH R HESS has written about Male.
Connection Strength
0.521
-
New option for the initial management of metastatic pancreatic cancer? J Clin Oncol. 2014 Aug 10; 32(23):2405-7.
Score: 0.015
-
Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. J Natl Compr Canc Netw. 2014 Feb; 12(2):194-203.
Score: 0.015
-
Glioblastoma resection. J Neurosurg. 2012 May; 116(5):1166-7; author reply 1167-8.
Score: 0.013
-
Metastatic patterns in adenocarcinoma. Cancer. 2006 Apr 01; 106(7):1624-33.
Score: 0.009
-
Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. J Neurooncol. 2006 May; 78(1):85-90.
Score: 0.008
-
Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol. 2003 04; 5(2):89-95.
Score: 0.007
-
Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res. 2000 Oct; 6(10):3878-84.
Score: 0.006
-
Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors. J Immunother Cancer. 2020 04; 8(1).
Score: 0.006
-
Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).
Score: 0.006
-
Sleep disturbance in patients with cancer: a feasibility study of multimodal therapy. BMJ Support Palliat Care. 2021 Jun; 11(2):170-179.
Score: 0.006
-
Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology. 2020 Apr; 20(3):501-504.
Score: 0.006
-
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res. 2020 04 15; 26(8):1924-1931.
Score: 0.006
-
Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res. 1999 Nov; 5(11):3403-10.
Score: 0.005
-
Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. JAMA Oncol. 2019 11 01; 5(11):1597-1604.
Score: 0.005
-
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909.
Score: 0.005
-
Response and progression in recurrent malignant glioma. Neuro Oncol. 1999 10; 1(4):282-8.
Score: 0.005
-
Somatotopy and Organization of Spinothalamic Tracts in the Human Cervical Spinal Cord. Neurosurgery. 2019 06 01; 84(6):E311-E317.
Score: 0.005
-
Risk of Distant Metastasis in Parathyroid Carcinoma and Its Effect on Survival: A Retrospective Review from a High-Volume Center. Ann Surg Oncol. 2019 Oct; 26(11):3593-3599.
Score: 0.005
-
Immediate Migration of Biopsy Clip Markers After Upright Digital Breast Tomosynthesis-Guided Vacuum-Assisted Core Biopsy. Acad Radiol. 2020 02; 27(2):204-209.
Score: 0.005
-
Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. J Med Internet Res. 2019 03 14; 21(3):e10348.
Score: 0.005
-
Minimally Invasive Cordotomy for Refractory Cancer Pain: A Randomized Controlled Trial. Oncologist. 2019 07; 24(7):e590-e596.
Score: 0.005
-
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. Cancer. 2019 02 01; 125(3):424-433.
Score: 0.005
-
Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother. 2018 Jul/Aug; 41(6):284-291.
Score: 0.005
-
An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology. 2018 10; 96:109-117.
Score: 0.005
-
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018 09 15; 24(18):4416-4428.
Score: 0.005
-
Imaging of Intracystic Papillary Carcinoma. Curr Probl Diagn Radiol. 2019 Jul - Aug; 48(4):348-352.
Score: 0.005
-
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322.
Score: 0.005
-
Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Thyroid. 2018 01; 28(1):79-87.
Score: 0.005
-
Volumetric response of progressing post-SRS lesions treated with laser interstitial thermal therapy. J Neurooncol. 2018 Mar; 137(1):57-65.
Score: 0.005
-
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2018 08; 36(4):638-646.
Score: 0.005
-
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Invest New Drugs. 2018 08; 36(4):601-607.
Score: 0.005
-
Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol. 2017 10; 125(1):80-88.
Score: 0.005
-
A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients With Advanced Cancer. J Natl Compr Canc Netw. 2017 09; 15(9):1111-1120.
Score: 0.005
-
Patterns of metastatic progression after definitive radiation therapy for early-stage and locally advanced non-small cell lung cancer. Clin Exp Metastasis. 2017 06; 34(5):315-322.
Score: 0.005
-
Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother Pharmacol. 2017 Sep; 80(3):583-589.
Score: 0.005
-
Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 08; 18(8):1040-1048.
Score: 0.005
-
Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Neuro Oncol. 2017 06 01; 19(6):786-795.
Score: 0.005
-
Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival. Neuro Oncol. 2017 05 01; 19(5):660-668.
Score: 0.005
-
Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol. 2017 09; 198(3):530-537.
Score: 0.005
-
Use of Spinal Cord Diffusion Tensor Imaging to Quantify Neural Ablation and Evaluate Outcome after Percutaneous Cordotomy for Intractable Cancer Pain. Stereotact Funct Neurosurg. 2017; 95(1):34-39.
Score: 0.005
-
Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 2016 Dec 27; 7(52):86280-86289.
Score: 0.005
-
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168.
Score: 0.004
-
Outcomes of patients =65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. Int J Cancer. 2017 Jan 01; 140(1):208-215.
Score: 0.004
-
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Sci Rep. 2016 10 17; 6:35448.
Score: 0.004
-
Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 2016 Sep 27; 7(39):64421-64430.
Score: 0.004
-
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396.
Score: 0.004
-
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemother Pharmacol. 2016 07; 78(1):167-71.
Score: 0.004
-
Are time or intensity factors important to the definition of metastases of unknown origin? J Natl Cancer Inst. 1996 Apr 03; 88(7):462-3.
Score: 0.004
-
Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. 2016 06 15; 122(12):1836-43.
Score: 0.004
-
Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. J Transl Med. 2016 Feb 09; 14:46.
Score: 0.004
-
Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget. 2015 Sep 29; 6(29):28453-62.
Score: 0.004
-
Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med. 1995 Aug 15; 14(15):1707-23.
Score: 0.004
-
The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. Oncologist. 2015 Jul; 20(7):737-41.
Score: 0.004
-
Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015 Jun; 16(6):695-703.
Score: 0.004
-
Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard? J Neurooncol. 2015 May; 123(1):141-50.
Score: 0.004
-
Prognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):349-57.
Score: 0.004
-
Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. Support Care Cancer. 2015 Sep; 23(9):2649-54.
Score: 0.004
-
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol. 2015 May; 26(5):1012-1018.
Score: 0.004
-
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget. 2014 Oct 15; 5(19):8937-46.
Score: 0.004
-
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol. 2015 Feb; 17(2):266-73.
Score: 0.004
-
MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clin Genitourin Cancer. 2015 Feb; 13(1):e19-26.
Score: 0.004
-
Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget. 2014 Jun 15; 5(11):3871-9.
Score: 0.004
-
Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. Invest New Drugs. 2014 Aug; 32(4):717-22.
Score: 0.004
-
Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist. 2014 Apr; 19(4):426-8.
Score: 0.004
-
Implications of bevacizumab discontinuation in adults with recurrent glioblastoma. Neuro Oncol. 2014 Jun; 16(6):823-8.
Score: 0.004
-
The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials. Ann Oncol. 2014 Jan; 25(1):276-82.
Score: 0.004
-
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol. 2014 Jan; 16(1):81-91.
Score: 0.004
-
A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases. Cancer Chemother Pharmacol. 2013 Apr; 71(4):955-63.
Score: 0.003
-
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan; 4(1):156-65.
Score: 0.003
-
Phospho-histone H3 (pHH3) immuno-reactivity as a prognostic marker in non-functioning pituitary adenomas. Pituitary. 2012 Dec; 15(4):556-61.
Score: 0.003
-
Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer. 2012 Jul 15; 118(14):3599-606.
Score: 0.003
-
Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer. Cancer Epidemiol. 2012 Apr; 36(2):206-11.
Score: 0.003
-
DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancer. Mol Carcinog. 2012 Jun; 51(6):491-9.
Score: 0.003
-
Glucose metabolism gene variants modulate the risk of pancreatic cancer. Cancer Prev Res (Phila). 2011 May; 4(5):758-66.
Score: 0.003
-
DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. Oncologist. 2011; 16(1):61-70.
Score: 0.003
-
Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer. Cancer. 2011 Feb 01; 117(3):480-91.
Score: 0.003
-
Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. Gastroenterology. 2010 Aug; 139(2):464-73, 473.e1-3.
Score: 0.003
-
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs. 2011 Aug; 29(4):694-9.
Score: 0.003
-
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009 Nov; 10(11):1037-44.
Score: 0.003
-
Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol. 2009 Sep; 94(2):229-34.
Score: 0.003
-
Prediction of left ventricular ejection fraction using a unique method of chest x-ray and ECG analysis: a noninvasive index of cardiac performance based on the concept of heart volume and mass interrelationship. Am Heart J. 1989 Mar; 117(3):590-8.
Score: 0.003
-
Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. J Clin Oncol. 2009 Apr 01; 27(10):1592-9.
Score: 0.003
-
Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer. 2008 Oct 15; 113(8):2046-52.
Score: 0.003
-
Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol. 2008 Sep 20; 26(27):4442-8.
Score: 0.003
-
Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro Oncol. 2008 Dec; 10(6):1010-8.
Score: 0.003
-
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol. 2008 Oct; 90(1):89-97.
Score: 0.002
-
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008 Mar 10; 26(8):1316-23.
Score: 0.002
-
A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol. 2008 Apr; 10(2):208-15.
Score: 0.002
-
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol. 2008 Apr; 10(2):216-22.
Score: 0.002
-
Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer. 2007 Nov 15; 110(10):2186-90.
Score: 0.002
-
Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6603-9.
Score: 0.002
-
Activation of polyamine catabolism by N1,N11-diethylnorspermine leads to cell death in glioblastoma. Int J Oncol. 2007 Aug; 31(2):431-40.
Score: 0.002
-
CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma. AJR Am J Roentgenol. 2007 Aug; 189(2):378-85.
Score: 0.002
-
Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 Jan 01; 13(1):234-40.
Score: 0.002
-
Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. Cancer. 2006 Dec 01; 107(11):2576-80.
Score: 0.002
-
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol. 2007 Feb; 81(3):271-7.
Score: 0.002
-
Complementary and alternative medicine use and quality of life in patients with primary brain tumors. J Pain Symptom Manage. 2006 Aug; 32(2):148-54.
Score: 0.002
-
Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. J Clin Oncol. 2006 Apr 01; 24(10):1627-32.
Score: 0.002
-
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2006 Apr; 8(2):189-93.
Score: 0.002
-
Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol. 2006 Apr 10; 24(11):1720-8.
Score: 0.002
-
The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer. 2005 Oct 01; 104(7):1468-77.
Score: 0.002
-
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005 Aug; 23(4):357-61.
Score: 0.002
-
Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol. 2005 May 01; 23(13):3094-103.
Score: 0.002
-
Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):440-9.
Score: 0.002
-
Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs. 2004 Nov; 22(4):427-35.
Score: 0.002
-
A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs. 2004 Nov; 22(4):459-66.
Score: 0.002
-
Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol. 2004 Nov 01; 22(21):4282-9.
Score: 0.002
-
13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro Oncol. 2004 Jul; 6(3):253-8.
Score: 0.002
-
Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004 Jun; 239(6):818-25; discussion 825-7.
Score: 0.002
-
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. Cancer. 2004 Apr 15; 100(8):1712-6.
Score: 0.002
-
Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer. 1994 Mar 01; 73(5):1533-5.
Score: 0.002
-
O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. Neuro Oncol. 2004 Jan; 6(1):28-32.
Score: 0.002
-
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neuro Oncol. 2004 Jan; 6(1):33-7.
Score: 0.002
-
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2004 Jan; 6(1):44-54.
Score: 0.002
-
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2003 Jun 15; 21(12):2305-11.
Score: 0.002
-
Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res. 2003 Mar; 9(3):981-90.
Score: 0.002
-
Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival. Oncology. 2003; 65(3):259-66.
Score: 0.002
-
Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2002 Sep 15; 20(18):3792-803.
Score: 0.002
-
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol. 2002 Sep 15; 20(18):3804-14.
Score: 0.002
-
Treatment outcomes of resected esophageal cancer. Ann Surg. 2002 Sep; 236(3):376-84; discussion 384-5.
Score: 0.002
-
Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer. 2002 Sep 01; 95(5):1120-6.
Score: 0.002
-
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys. 2002 May 01; 53(1):58-66.
Score: 0.002
-
A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro Oncol. 2002 Apr; 4(2):109-14.
Score: 0.002
-
Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol. 2002 Mar 01; 20(5):1383-8.
Score: 0.002
-
CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980. Cancer Invest. 2002; 20(7-8):948-54.
Score: 0.002
-
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001 Aug; 95(2):190-8.
Score: 0.002
-
Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann Surg. 2001 Jul; 234(1):47-55.
Score: 0.002
-
Survival and recurrence factors in adult medulloblastoma: the M.D. Anderson Cancer Center experience from 1978 to 1998. Neuro Oncol. 2001 07; 3(3):167-73.
Score: 0.002
-
Surgery for abdominal metastases of cutaneous melanoma. World J Surg. 2001 Jun; 25(6):750-8.
Score: 0.002
-
Phase I bioequivalency study of MitoExtra and mitomycin C in patients with solid tumors. Cancer. 2001 Feb 15; 91(4):815-21.
Score: 0.002
-
Correlation of kidney weight and volume and selected skeletal parameters to sex in the adult rhesus monkey (Macaca mulatta). J Med Primatol. 2001 Feb; 30(1):56-60.
Score: 0.001
-
Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas. J Clin Oncol. 2000 Oct 01; 18(19):3378-83.
Score: 0.001
-
Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol. 2000 Feb; 18(3):646-50.
Score: 0.001
-
A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1999 Aug 01; 45(1):127-35.
Score: 0.001
-
Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. J Gastrointest Surg. 1999 May-Jun; 3(3):263-77.
Score: 0.001
-
Gamma-ray mutagen sensitivity and survival in patients with glioma. Clin Cancer Res. 1998 Dec; 4(12):3031-5.
Score: 0.001
-
Ependymomas: MIB-1 proliferation index and survival. J Neurooncol. 1998 Oct; 40(1):51-7.
Score: 0.001
-
Cancer among a Michigan cohort exposed to polybrominated biphenyls in 1973. Epidemiology. 1998 Jul; 9(4):373-8.
Score: 0.001
-
Reduction of neurologic injury after high-risk thoracoabdominal aortic operation. Ann Thorac Surg. 1998 Jul; 66(1):132-8.
Score: 0.001
-
Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery. 1998 May; 42(5):1044-55; discussion 1055-6.
Score: 0.001
-
p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res. 1997 Oct; 3(10):1685-90.
Score: 0.001
-
Screening for colorectal cancer. A comparison of 3 fecal occult blood tests. Arch Intern Med. 1997 May 12; 157(9):970-6.
Score: 0.001
-
Pelvic exenteration for locally advanced rectal carcinoma: factors predicting improved survival. Surgery. 1997 May; 121(5):479-87.
Score: 0.001
-
Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma? J Clin Oncol. 1997 May; 15(5):2056-66.
Score: 0.001
-
Evaluation of sister chromatid exchange and chromosome breaks in a cohort of untreated Hodgkin's disease patients. Cancer Epidemiol Biomarkers Prev. 1997 Apr; 6(4):291-3.
Score: 0.001
-
TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol. 1997 Mar; 15(3):1063-70.
Score: 0.001
-
Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. Clin Cancer Res. 1996 Sep; 2(9):1489-97.
Score: 0.001
-
Surgery versus radiosurgery in the treatment of brain metastasis. J Neurosurg. 1996 May; 84(5):748-54.
Score: 0.001
-
Prognostic significance of p53 immunoreactivity in patients with glioma. Clin Cancer Res. 1995 Dec; 1(12):1617-22.
Score: 0.001
-
Reoperation for recurrent metastatic brain tumors. J Neurosurg. 1995 Oct; 83(4):600-4.
Score: 0.001
-
Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995 Aug; 13(8):2094-103.
Score: 0.001
-
Aggressive meningeal tumors: review of a series. J Neurosurg. 1995 Jan; 82(1):17-27.
Score: 0.001
-
Influence of segmental arteries, extent, and atriofemoral bypass on postoperative paraplegia after thoracoabdominal aortic operations. J Vasc Surg. 1994 Aug; 20(2):255-62.
Score: 0.001
-
Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994 Jun; 12(6):1272-80.
Score: 0.001
-
Primary adenocarcinoma of the duodenum: management and survival in 67 patients. Ann Surg Oncol. 1994 Jan; 1(1):73-8.
Score: 0.001
-
Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer. 1993 May 15; 71(10):3119-23.
Score: 0.001
-
Percutaneous transluminal coronary angioplasty utilizing prolonged balloon inflations: initial results and six-month follow-up. Cathet Cardiovasc Diagn. 1991 Aug; 23(4):239-44.
Score: 0.001
-
Thoracoabdominal aortic aneurysms: preoperative and intraoperative factors determining immediate and long-term results of operations in 605 patients. J Vasc Surg. 1986 Mar; 3(3):389-404.
Score: 0.001